Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Agios Pharmaceuticals, Inc. (NASDAQ: AGIO).

Full DD Report for AGIO

You must become a subscriber to view this report.


Recent News from (NASDAQ: AGIO)

Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Corcept Therapeutics Incorporat...
Source: GlobeNewswire
Date: May, 17 2018 07:50
Biotechs Emerge Unscathed And Ready To Go!
Biotech Pulse Biotechs have a pulse now, and it's beginning to beat a little harder! As President Trump on Friday, May 11, delivered a blueprint, American Patients First , to lower drug prices the early indications appear to be that the biotech and pharmaceutical industries have jumped th...
Source: SeekingAlpha
Date: May, 15 2018 08:28
A Fresh Look At Celgene After Q1 And New Info On Ozanimod
Introduction - A perplexing stock This article covers issues about Celgene (CELG) that are on my mind, some of which may be on the minds of various investors, large and small. This stock was one of my few significant investment disappointments last year in what was otherwise a very fine year...
Source: SeekingAlpha
Date: May, 08 2018 05:10
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Investor Day 2018 Results - Earnings Call Transcript
Agios Pharmaceuticals, Inc. (AGIO) Investor Day 2018 Results Earnings Conference Call May 04, 2018, 08:00 AM ET Executives David Schenkein - CEO Scott Biller - Chief Scientific Officer Kevin Marks - Senior Director, Head of Cancer Biology Darrin Miles - Vice President, IDH Prog...
Source: SeekingAlpha
Date: May, 06 2018 00:49
Agios Pharmaceuticals (AGIO) Investor Presentation - Slideshow
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 04 2018 14:07
Agios Pharmaceuticals EPS in-line, misses on revenue
Agios Pharmaceuticals (NASDAQ: AGIO ): Q1 EPS of -$1.63 in-line. More news on: Agios Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 04 2018 07:05
Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day
– Commercial Infrastructure In Place Ahead of August 21, 2018 PDUFA Action Date for TIBSOVO ® (Ivosidenib) for IDH1m R/R AML – – Clinical Portfolio Advancing with Four Compounds in Development and Five Pivotal Trials Ongoing or Planned Across Three Dis...
Source: GlobeNewswire
Date: May, 04 2018 07:00
Notable earnings before Friday's open
ABR , ACAD , AGIO , AON , ASIX , AXL , BABA , BCC , BPL , CBOE , CELG , CIO , CNP , DOC , ESNT , GEL , GLOG , GOGO , HMSY , IDXX , IMGN , IONS , ITT , LCII , LNG , LPNT , NJR , NWL , ROCK , RUTH , STWD , TRTN , TWI , VER , VIRT , VST , WPC For Seekin...
Source: SeekingAlpha
Date: May, 03 2018 17:30
Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018
CAMBRIDGE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations from its Investor Day, including first quarter ...
Source: GlobeNewswire
Date: April, 27 2018 07:00
ASLAN Pharmaceuticals Updates U.S. IPO Plans
Quick Take ASLAN Pharmaceuticals ( ASLN ) intends to raise $60.4 million from the sale of ADSs in a U.S. IPO . The company targets cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe. ASLN is making excellent progress on its pipeline o...
Source: SeekingAlpha
Date: April, 18 2018 17:49

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1786.4786.0186.7984.95157,587
2017-06-2051.8952.7554.2551.42764,640
2017-06-1952.0151.7652.6551.26427,255
2017-06-1650.4651.7751.8550.0611569,726
2017-06-1550.8650.5151.5549.76423,704

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1390,023281,01532.0349Cover
2018-08-1037,176132,39028.0807Cover
2018-08-0960,335135,06844.6701Short
2018-08-0854,102100,96053.5876Short
2018-08-0720,28096,41721.0336Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AGIO.


About Agios Pharmaceuticals, Inc. (NASDAQ: AGIO)

Logo for Agios Pharmaceuticals, Inc. (NASDAQ: AGIO)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: AGIO)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 04 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 18 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 18 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 13 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 14 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 14 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: AGIO)

      Daily Technical Chart for (NASDAQ: AGIO)


      Stay tuned for daily updates and more on (NASDAQ: AGIO)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: AGIO)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AGIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AGIO and does not buy, sell, or trade any shares of AGIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/